相关实验视频

Updated: Jun 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

CDK12突变在PCa发展和治疗中的作用

Chenye Jiang¹, Zhe Hong¹, Shiwei Liu¹

¹Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Genitourinary Cancer Institute, Shanghai 200032, China.

Biochimica et biophysica acta. Reviews on cancer

|December 16, 2024

概括

循环素依赖性激酶12 (CDK12) 突变驱动前列腺癌 (PCa) 的进展和对治疗的抗性. 了解这些变化,包括同源重组缺陷 (HRD) 和新抗原,为高级PCa提供了新的治疗途径.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

前列腺癌 (PCa) 是男性的主要癌症.
在PCa的发育和进展到耐割PCa (CRPC) 中,循环素依赖性激酶12 (CDK12) 突变越来越多地被识别出来.
CDK12的变化,包括功能丧失突变,内基多基化 (IPA),焦点串联重复 (FTD) 和R环,影响基因表达和基因组稳定性.

研究的目的:

审查CDK12突变在PCa瘤发生和进展中的多方面的作用.
讨论PCa中CDK12变化的临床意义.
探索CDK12作为PCa.的潜在治疗点.

主要方法:

文献综述综合了PCa.中关于CDK12的当前研究.
对突变类型 (IPA,FTD) 和其后果 (HRD,新抗原,AR信号) 的分析.
讨论R循环,转录复制冲突 (TRCs) 以及它们对细胞的影响.

主要成果:

CDK12突变与同源重组缺陷 (HRD) 和雄激素受体 (AR) 路径改变有关.
由CDK12突变驱动的FTD可以增加新抗原负载和AR和MYC等关键癌基因的表达.
由CDK12变异引起的R环和TRCs会影响基因表达和基因组完整性.

结论:

CDK12突变PCa的预后不佳,对标准疗法反应有限.
在CDK12突变PCa中,HRD和新抗原生成为新的治疗策略提供了机会.
在PCa治疗中,CDK12是未来研究和临床开发的有希望的目标.

关键词:

在CDK12突变中.焦点串联重复的重复.同类的重组组合.免疫检查点抑制剂免疫检查点抑制剂内部的多基化.PARP 抑制剂的使用前列腺癌是什么意思前列腺癌是什么意思在R-Loop中使用.转录-复制冲突发生.

更多相关视频

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Murine Prostate Micro-dissection and Surgical Castration

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...